European consensus conference on unruptured brain AVMs treatment (Supported by EANS, ESMINT, EGKS, and SINCH)
Language English Country Austria Media print-electronic
Document type Journal Article
PubMed
28389875
DOI
10.1007/s00701-017-3154-8
PII: 10.1007/s00701-017-3154-8
Knihovny.cz E-resources
- Keywords
- ARUBA, Arteriovenous malformation, Consensus Conference, EANS, EGKS, ESMINT, Unruptured brain AVM,
- MeSH
- European Union MeSH
- Intracranial Arteriovenous Malformations surgery MeSH
- Congresses as Topic MeSH
- Consensus * MeSH
- Humans MeSH
- Neurosurgical Procedures standards MeSH
- Randomized Controlled Trials as Topic standards MeSH
- Registries standards MeSH
- Practice Guidelines as Topic * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler-Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.
Neurology Grande Ospedale Metropolitano Niguarda Milan Italy
Neurology Methodologist IRCCS Istituto Mario Negri Milan Italy
Neuroradiology Bicetre University Hospital Paris France
Neuroradiology Cerrahpaşa Medical Faculty İstanbul University Istanbul Turkey
Neuroradiology Krupp Hospital Hessen Germany
Neuroradiology Metropolitan Hospital Niguarda Milan Italy
Neuroradiology National Institute of NeuroScience Budapest Hungary
Neurosurgery and Neuroradiology University Hospital Lintz Austria
Neurosurgery Burdenko Hospital Moscow Russia
Neurosurgery Charitè Universitatetsmedizin Berlin Germany
Neurosurgery Grande Ospedale Metropolitano Niguarda Milan Italy
Neurosurgery Inselspital Bern Switzerland
Neurosurgery Macquaire University Sydney Australia
Neurosurgery National Hospital Oslo Norway
Neurosurgery Ospedale Maggiore Civile Verona Italy
Neurosurgery UniversitaetsSpital Zurich Switzerland
Neurosurgery University Hospital Helsinki Finland
Radiosurgery Bupa Cromwell Hospital London UK
Radiosurgery Burdenko Hospital Moscow Russia
Radiosurgery Grande Ospedale Metropolitano Niguarda Milan Italy
Radiosurgery Na Homolce Hospital Prague Czech Republic
Radiosurgery Ospedale Villa Maria di Cotignola Ravenna Italy
Radiosurgery Royal Hallamshire Hospital Sheffield UK
Radiosurgery Singapore Gamma Knife Center Singapore Singapore
References provided by Crossref.org
